Loading
Allarity Therapeutics, Inc. Stock: price and insider trades · United States
Allarity Therapeutics, Inc.: what insiders have been doing
Allarity Therapeutics, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). In the past year (22 October 2025 to 22 October 2026), 8 filings came from 3 insiders.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
Insider buying of Allarity Therapeutics, Inc. has been absent for the past year.
Across the 3,171 companies tracked on its exchange, the median is 24 filings; at 8 filings, this issuer sits below that mark. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 320,000 USD and net income at -11.2 m USD.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
14
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.88
Analyst consensus
1 analysts1.00/5
US$11.00Target US$11.00(+1151%)US$11.00
Income statement
RevenueUS$320k
Gross profit-US$2M-609% margin
EBITDA-US$11M-3452% margin
Net income-US$11.2M-3509.7% margin
Valuation
PER (forward)-1.0x
P/Book4.0x
Beta0.57
Balance sheet & cash
Market capUS$14M
Total debtUS$1.4M
Free Cash Flow-US$14.8M
Debt / Equity630%
Profitability & ownership
ROE-157.1%
ROA-25.3%
% insiders0.3%
% institutions8.1%
Last declaration on 9 October 2026
Declarations14 total
48,147 sharesCommon StockSEC:0001213900-26-108573:0
17,814 shares@ US$1.187.1% of flowCommon StockSEC:0001213900-26-108573:1
39,494 sharesCommon StockSEC:0001213900-26-108573:2
14,613 shares@ US$0.970.063% mcap4.9% of flowCommon StockSEC:0001213900-26-108573:3
200,000 shares0Common StockSEC:0001213900-26-056373:0
150,000 shares0Common StockSEC:0001213900-26-050131:0
133,333 shares0Common StockSEC:0001213900-26-050133:0
133,333 shares0Common StockSEC:0001213900-26-005146:0
14,613 shares@ US$1.587.2% of flowCommon StockSEC:0001213900-25-095391:1
39,494 sharesCommon StockSEC:0001213900-25-095391:0
144,441 shares0Common StockSEC:0001437749-25-001808:0
29,496 shares0Common StockSEC:0001437749-25-001806:0
396,734 shares0Common StockSEC:0001437749-25-001801:0
118,483 shares@ US$2.11100.0% of flowCommon StockSEC:0001213900-24-084163:0
14 of 14 declarations
About Allarity Therapeutics, Inc.
Allarity Therapeutics, Inc. (ticker: ALLR) is a United States-based clinical-stage biopharmaceutical company listed on NASDAQ. The company’s strategy is built around precision oncology: it develops cancer therapies alongside its proprietary Drug Response Predictor (DRP®) platform, which is intended to identify the patients most likely to benefit from a given therapy. In practical terms, Allarity is trying to improve clinical success rates by better matching drug and patient, rather than by relying on broad, one-size-fits-all oncology development.
Allarity traces its origins to Denmark. According to company disclosures, the business was founded in 2004 as Medical Prognosis Institute A/S, with foundational work led by Steen Knudsen, Ph.D., and Thomas H. Jensen around bioinformatics and diagnostic approaches aimed at improving cancer treatment response. The company later restructured and became Allarity Therapeutics. Today, its corporate headquarters are in Boston, Massachusetts, while it maintains an R&D presence in Hørsholm, Denmark. That transatlantic footprint reflects both its U.S. public-market base and its European scientific roots.
Read moreShow less
From a business-line perspective, Allarity is primarily focused on stenoparib (2X-121), a differentiated dual PARP and WNT/Tankyrase pathway inhibitor being developed for difficult-to-treat cancers, especially advanced recurrent ovarian cancer. The company also advances companion diagnostic capabilities built on its DRP® technology, which it uses to support patient selection in clinical trials and, in theory, to enhance both efficacy and development efficiency. This places Allarity in a highly competitive oncology biotech niche where differentiation depends on clinical data, biomarker validation, and access to capital.
Its market position is that of a small-cap, high-risk, data-driven oncology developer rather than a diversified pharmaceutical platform. The competitive set includes other precision oncology and PARP-focused companies, but Allarity’s main differentiator is the combination of stenoparib plus DRP-guided enrollment. The company has also referenced additional exploratory work in cancers beyond ovarian, including small cell lung cancer and colorectal cancer, although stenoparib remains the core asset.
Recent developments have been important. In 2025 and 2026, Allarity reported ongoing Phase 2 activity, including updated clinical data presented at major scientific meetings such as AACR and SGO, and it received FDA Fast Track designation for stenoparib in advanced ovarian cancer. In March 2026, the company announced approximately $20 million in non-convertible debt financing, which it said would support completion of Phase 2 work, regulatory preparation, and progress toward a potential pivotal trial. For investors, ALLR remains a speculative NASDAQ-listed oncology story in the United States, with value creation heavily tied to clinical execution, regulatory milestones, and the eventual validation of its DRP®-guided development model.
